

NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING
AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Sunday, October 19, 2003 - 9:00 a.m. - 4:15 p.m.
Room: Mountbatten Salon B

Chair: Drs. J Gregory Cairncross, Warren Mason

7:30 a.m. Executive meeting (CLOSED) Room: James

9:00 a.m. Welcome and Introduction G. Cairncross

COMPLETED STUDIES

9:15 a.m. CE-2- PCV plus RT vs RT for oligodendroglioma-status G. Cairncross

9: 30 a.m. CE-3- Temozolomide plus RT vs RT for GBM-status G. Cairncross /W. Mason

9: 45 a.m. IND 109- Topotecan for oligodendroglioma - manuscript status E. Eisenhower

10:00 a.m. IND 139- T138067 Na - manuscript status S. Kirby

10:15 a.m. IND 142-SarCNU- update G. Cairncross

10:30 a.m. **COFFEE BREAK**

NEW TRIALS

10:45 a.m. Update on March 2003 EORTC Brain Site meeting W. Mason

11:00 a.m. Phase III studies of RT vs observation for newly-diagnosed meningiomas R. Del Maestro

11:15 a.m. RT studies for elderly GBM G. Cairncross

11:30 a.m. Phase III study of RT vs Temozolomide for low-grade glioma W. Mason

11:45 a.m. Phase II studies for rare brain tumors

12:00 p.m. **LUNCH**

continued . . .

continued . . .

FUTURE NCIC PHASE I/II STUDIES

- | | | |
|------------|---|---|
| 1:00 p.m. | Report from NCIC-EORTC-NCI workshop to identify molecular targets for drug development in glioma
Toronto, July 2002 | G.Cairncross
E. Eisenhauer
W. Mason |
| 1:30 p.m. | Report from EORTC Radiotherapy Group brainstorming meeting to plan new phase I/ II studies for brain tumours
Geneva, December 2002 | G. Cairncross
W. Mason |
| 2:00 p.m. | Phase I/II Study of RAD 001c/TMZ in recurrent GBM | E.Eisenhauer
W. Mason |
| 2:30 p.m. | COFFEE BREAK | |
| 3:00 p.m. | Report from NCIC CTG IND Meeting | W. Mason |
| 3:15 p.m. | Ideas for new GBM studies | G. Cairncross |
| 3:30 P.M. | ADJOURN | |
| 3:30-4:15: | Executive Meeting (Closed) | |